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Background:  Hyperkalemia (HK) frequently develops in patients (pts) with heart failure or chronic kidney disease treated with RAAS 
inhibitors (RAASi). Continuation of these cardiorenal protective agents is desirable but limited by HK. Sodium zirconium cyclosilicate (ZS-
9), a nonabsorbed cation exchanger that specifically traps K+ in the GI tract, acutely restored and maintained normokalemia in HK pts 
in a Phase 3 study. In this subgroup analysis, we evaluated whether once daily (QD) ZS-9 could prevent hyperkalemia in pts on RAASi 
therapies.
methods:  This phase 3 study enrolled 753 pts with serum K+ 5.0-6.5 mEq/L who were initially randomized to thrice daily ZS-9 or placebo 
for 48hrs. Of these, 166 pts who had normalized K+ and were on RAASi were randomized to QD ZS-9 at 5 or 10 g, or PBO for 2 weeks 
of maintenance therapy. Per protocol, RAASi dose was continued unchanged for the duration of the study. Unpaired t-tests were used to 
compare K+ between the two groups.
results:  Baseline K+ following normalization was similar in the ZS-9 and PBO groups (4.55 mEq/L and 4.64 mEq/L, respectively). Pts 
on ZS-9 maintained normokalemia (4.67 mEq/L), whereas those receiving PBO trended back to hyperkalemia by Day 15 (5.06 mEq/L; 
p<0.05). (Figure).
conclusion:  In pts on RAASi, ZS-9 effectively prevented hyperkalemia compared with placebo, indicating that this novel K+-lowering 
agent may facilitate continued use of the cardioprotective RAASi by effectively maintaining normokalemia.
 
